Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Business Insider on MSN6d
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Healthcare Dive11d
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...
Lexaria Bioscience price target lowered to $7 from $10 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $7 from $10 and keeps a Buy rating on the ...
Yahoo Finance8d
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
Eli Lilly markets its tirzepatide medicines, Mounjaro for T2D and Zepbound for obesity, which competes with NVO’s Ozempic and Wegovy. The fall in LLY’s stock price is likely because investors ...
The Financial Express8d
Blockbuster weight loss drug Tirzepatide coming to India soon: Benefits, weight loss potential, and side effects
Weight loss drugs like Ozempic and wegovy have become global sensation. In the recent years, companies like Novo Nordisk and Eli Lilly have GLP-1 agonists and dual GLP-1/GIP receptor agonists that ...